Please login to the form below
everolimus
This page shows the latest everolimus news and features for those working in and with pharma, biotech and healthcare.
BMS unveils long-term results for Opdivo in kidney cancer
alive at this time-point compared to 18% of those treated only with the standard chemotherapy drug everolimus.
Latest news
-
NICE nod for Lilly’s breast cancer drug Verzenio via CDF
NICE notes in its guidance that Verzenio and fulvestrant will be an option “where exemestane plus everolimus would be the most appropriate alternative treatment.”. ... On that point, Baroness Morgan said that as everolimus with exemestane is
-
Afinitor and Uptravi gain funding from NHS England
Around 70 people in England are currently prescribed everolimus for TSC-related kidney and brain tumours. ... NHS England estimates that a further 300 people in England will benefit from treatment with everolimus for TSC-related refractory epilepsy.
-
$5.76bn deal puts Merck closer to Eisai and fast-growing Lenvima
First approved in 2015 for refractory thyroid cancer, Lenvima has subsequently been given the nod as a second-line treatment for renal cell carcinoma in combination with everolimus and has been
-
AAA board presses go on $3.9bn Novartis takeover
Novartis has no heritage in this type of medicine but already markets two drugs for NET – Sandostatin (octreotide) and Afinitor/Votubia (everolimus) – so the acquisition makes sense from a franchise perspective,
-
NICE U-turn on Novartis' Afinitor for kidney cancer
cancer. The U-turn on NICE's 2011 decision comes as the regulator continues its reappraisal of all therapies supported by the Cancer Drugs Fund (CDF), with Afinitor (everolimus) previously only
More from news
Approximately 8 fully matching, plus 64 partially matching documents found.
Latest from PMHub
-
Oncology drugs under AMNOG
patients the comparator was a different targeted therapy, Afinitor (everolimus), rather than Nexavar - although for cytokine-pretreated patients the trial comparator could be used.The G-BA still exercises its right
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- New study identifies drugs that are safe to use in COVID-19 treatment
- How COVID-19 is accelerating the threat of antimicrobial resistance
- Relief Therapeutics seeks US emergency approval for COVID-19 drug
- FDA hands BMS and bluebird bio a priority review for ide-cel
- BMS eyes approval for second Opdivo combo in kidney cancer
- Pfizer helps fund biotech venture from former researchers at closed Kent facility
- Live Webinar: Leveraging Digital Technologies to Create Valuable KOL Engagements & Empower Patients
- Live Webinar: Harnessing Technology to Improve Health and Healthcare
- Novavax starts first phase 3 COVID-19 vaccine trial in the UK
- Lilly’s Verzenio scores a win in early-stage breast cancer
- FDA sets January decision date for Xalkori in ALK-positive lymphoma
- Q&A: Isabel Gibson
PMHub
AMICULUM Limited
AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...
Latest intelligence
- Surviving cancer: a new era for patients
- Now more than ever, a shift in perspective is needed...
- Crisis? No problem!
- Issues planning & management for pharma spokespeople, by Andrew Smith...
- Are patient recruitment and retention rates rising or falling?
- First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....
Quick links
Infographics
